DAFNA Capital Trims Axogen Stake Amid 71% Stock Surge and Strong Revenue Growth

The decision by DAFNA Capital Management to reduce its exposure to Axogen (AXGN) comes at a pivotal moment for the medical device manufacturer, which has seen its valuation swell by 71% over the past year. According to recent SEC filings, the healthcare-focused investment firm sold 265,456 shares during the fourth quarter of 2025, a move valued at approximately $6.53 million based on quarterly average pricing. This transaction represents a 35% reduction in DAFNA’s total Axogen holdings, yet the company remains a significant component of the fund’s portfolio, accounting for 3.63% of its reportable assets. This strategic 'trim' is characteristic of institutional profit-taking following a period of exceptional market outperformance, particularly as Axogen has significantly outpaced the S&P 500’s 15% gain over the same period.

Axogen’s market strength is rooted in its specialized focus on peripheral nerve repair and regeneration, a niche within the medical device sector that has seen increasing clinical adoption. The company’s 20% revenue growth is largely attributed to its comprehensive product ecosystem, which includes the Avance Nerve Graft—a processed human nerve allograft—and the AxoGuard line of nerve connectors and protectors. By providing surgeons with biologically active solutions rather than traditional synthetic alternatives, Axogen has established a high barrier to entry. The company serves a broad spectrum of surgical specialties, including orthopedic, plastic reconstructive, and oral maxillofacial surgeons, positioning it as a critical supplier in both elective and trauma-related surgical centers.

“

This transaction represents a 35% reduction in DAFNA’s total Axogen holdings, yet the company remains a significant component of the fund’s portfolio, accounting for 3.63% of its reportable assets.

From a portfolio management perspective, DAFNA’s reallocation of capital highlights a broader trend among healthcare investors to balance high-growth device makers with late-stage biopharmaceutical plays. DAFNA’s top holdings currently include Revolution Medicines (RVMD), which commands over 11% of the fund’s assets, and the SPDR S&P Biotech ETF (XBI). By maintaining a $15.61 million stake in Axogen, DAFNA signals continued confidence in the company’s long-term trajectory while diversifying into other high-conviction areas like robotic surgery (Stereotaxis) and atrial fibrillation treatments (AtriCure). This rebalancing act is essential in a volatile biotech environment where clinical milestones and regulatory shifts can rapidly alter valuation landscapes.